Triamcinolone acetonide mouth rinses for treatment of erosive oral lichen planus: efficacy and risk of fungal over-infection.
OBJECTIVE
To assess the efficacy of triamcinolone acetonide mouthrinse for treatment of erosive oral lichen planus (OLP), and to evaluate the risk of fungal over-infection.


METHODS
Clinical records of all cases of erosive and erosive-ulcerative OLP treated in our Oral Medicine Service over the period 1993-2003 were reviewed. All patients had been treated with mouthrinses containing triamcinolone acetonide at 0.3% (T1) or 0.5% (T2). Clinical outcome for each patient was classified at 1, 3 and 6 months after start of treatment as total remission (TR), partial remission (PR) or no remission (NR). Fungal over-infection was also recorded.


RESULTS
A total of 35 cases were included in the study. Clinical outcomes considering both treatment groups together (T1 + T2) were as follows: at month 1, 28.6% TR, 62.9% PR, 8.6% NR; at month 3, 57.1% TR, 37.1% PR, 5.7% NR; and at month 6, 80.0% TR, 17.1% PR, 2.9% NR. In four patients (11.4%) fungal over-infection was noted during the study period.


CONCLUSIONS
Triamcinolone acetonide mouthrinse is an appropriate treatment for erosive OLP, in view of the high efficacy and low risk of fungal over-infection.
González-García
A
A
Department of Oral Surgery and Oral Medicine, School of Dentistry, University of Santiago de Compostela, Santiago de Compostela, Spain. gonzalezygarcia@gmail.com
Diniz-Freitas
M
M
Gándara-Vila
P
P
Blanco-Carrión
A
A
García-García
A
A
Gándara-Rey
Jm
J
D000328:Adult; D000368:Aged; D002180:Candidiasis, Oral / Q000209:etiology*; D005260:Female; D005938:Glucocorticoids / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D017676:Lichen Planus, Oral / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009067:Mouthwashes / Q000627:therapeutic use*; D012189:Retrospective Studies; D015163:Superinfection; D014222:Triamcinolone Acetonide / Q000008:administration & dosage / Q000627:therapeutic use*
D005938:Glucocorticoids; D009067:Mouthwashes; D014222:Triamcinolone Acetonide